Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "distant metastases" wg kryterium: Wszystkie pola


Wyświetlanie 1-4 z 4
Tytuł:
Immunohistochemical Fascin-1 expression correlate with lymph node and distant metastases in pancreatic ductal adenocarcinoma
Autorzy:
Pryczynicz, A.
Nizioł, M.
Miniewska, K.
Kamińska, D.
Kuczyńska, P.
Zińczuk, J.
Zaręba, K.
Guzińska-Ustymowicz, K.
Powiązania:
https://bibliotekanauki.pl/articles/1918748.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Fascin-1
metastases
pancreatic ductal adenocarcinoma
Opis:
Introduction: Pancreatic cancer is characterized by its aggressiveness and poor prognosis. Furthermore, mortality is one of the highest among all types of cancers. It has been observed that the expression of Fascin-1 (the actin-bundling protein which enables the motility of cells) is higher in cancer cells and is correlated with invasiveness and metastasis. Purpose: To investigate the expression of Fascin-1 in histopathological specimens from patients treated for pancreatic cancer and its relationship with histopathological parameters. Materials and methods: The study was performed on a group of 52 patients diagnosed with pancreatic cancer in the Medical University of Bialystok Clinical Hospital. The expression of Fascin-1 was evaluated in tissue samples using the immunohistochemical method and was rated as “present” or “absent”. The analysis of histopathological parameters was performed in correlation with Fascin-1 expression. Results: Fascin-1 expression was observed in the cytoplasm of cancer cells in 42/52 cases (80.8%). Fascin-1 expression occurred more frequently among patients with lymph node metastases (92.6%) than without this type of metastases (68%) (p=0.024). Likewise, the expression of the investigated protein was observed more often with the presence of distant metastases (100%) than without those metastases (74.4%) (p=0.043). There were no statistically significant differences about age, sex, histological type of cancer, grade of histological differentiation, desmoplasia, inflammatory infiltration, foci of hemorrhage, necrosis, and MVD. Conclusion: The expression of Fasicn-1 is correlated with the presence of metastases and can be a useful marker of pancreatic cancer involvement.
Źródło:
Progress in Health Sciences; 2018, 8(2); 124-130
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Skojarzone leczenie chorych na mięsaki macicy – ocena wyników i analiza czynników prognostycznych
Combined therapy of patients with uterine sarcomas – evaluation of treatment results and analysis of prognostic factors
Autorzy:
Michalak, Andrzej
Karolewski, Kazimierz
Jakubowicz, Jerzy
Blacharz, Paweł
Dymek, Paweł
Piwowarczyk, Sławomir
Powiązania:
https://bibliotekanauki.pl/articles/908155.pdf
Data publikacji:
2006
Wydawca:
Medical Communications
Tematy:
distant metastases
radiotherapy
sarcoma uteri
surgery
treatment failure
Opis:
Objectives: The aim of the study was to assess the efficacy of combined therapy (surgery plus radiotherapy) and reasons of treatment failure in patients with uterine sarcoma. Material and methods: The analyzed clinical material involved 95 patients with uterine sarcoma (US) treated in the Cracow Branch of the Center of Oncology between 1980 and 1999. The studied group consisted of 70 patients with leiomyosarcoma (LS) and 25 patients with endometrial stromal sarcoma (ESS). Seventy-three women were diagnosed with stage I and II and 22 with stage III and IVA US. All patients in this group underwent radical hysterectomy with salpingooophorectomy followed by postoperative irradiation consisting of vaginal brachytherapy and external beam radiotherapy of the small pelvic area. Results: Out of 95 patients in the tested group, 46 (48.4%) patients survived 5 years with no evidence of disease. In the group of early-stage US there were 60.3% 5-year disease-free survivals. None of 9 patients with stage IVA was cured. In 36 among 47 uncured patients (76.6%) distant metastases was found. Conclusion: Combined surgery plus radiotherapy treatment was effective therapy in patients with early-stage US, nevertheless, it was ineffective in the group with advanced US, as none of the 9 patients with grade IVA was cured. The basic cause of treatment failure in the LS group was the spread of malignancy, whereas in the ESS group – locoregional recurrence.
Cel: Celem pracy była ocena skuteczności leczenia skojarzonego (chirurgia + napromienianie) i analiza przyczyn niepowodzenia leczenia chorych na mięsaka macicy. Materiał i metody: Przeprowadzono analizę materiału klinicznego obejmującego 95 chorych na mięsaka macicy (MM) leczonych w Centrum Onkologii, Oddział Kraków w latach 1980-1999. W skład badanej grupy weszło 70 chorych na leiomyosarcoma (LS) oraz 25 chorych na endometrial stromal sarcoma (ESS). U 73 pacjentek rozpoznano MM w I i II, a u 22 w III i IVA stopniu zaawansowania. W badanej grupie u wszystkich chorych wykonano zabieg radykalnego usunięcia macicy wraz z przydatkami, a następnie przeprowadzono uzupełniające pooperacyjne napromienianie składające się z brachyterapii dopochwowej i teleradioterapii terenu miednicy mniejszej. Wyniki: Spośród 95 chorych z badanej grupy 5 lat bez objawów nowotworu przeżyło 46, tzn. 48,4% chorych. W grupie osób z niezaawansowanym MM uzyskano 60,3% bezobjawowych przeżyć 5-letnich. Skojarzone leczenie chirurgiczne z pooperacyjnym napromienianiem okazało się nieskuteczne w grupie chorych na zaawansowanego MM – nie wyleczono żadnej spośród 9 chorych w IVA stopniu zaawansowania. U 36 spośród 47 chorych (76,6%) z niewyleczonym procesem nowotworowym stwierdzono przerzuty odległe. Wnioski: Skojarzone leczenie chirurgiczne z pooperacyjnym napromienianiem było skuteczne u chorych na niezaawansowanego MM, natomiast u chorych na zaawansowanego MM skojarzone leczenie okazało się nieskuteczne, ponieważ żadna z 9 chorych na MM w stopniu IVA nie została wyleczona. Głównym powodem niepowodzenia leczenia w grupie chorych na LS były przerzuty odległe, a w grupie chorych na ESS – wznowa lokoregionalna.
Źródło:
Ginekologia Onkologiczna; 2006, 4, 1; 23-30
1731-5379
Pojawia się w:
Ginekologia Onkologiczna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The growth differentiation factor-15 (GDF-15) can be useful in the detection of distant metastases in sera of colorectal cancer patients
Autorzy:
Jakubowska, K.
Pryczynicz, A.
Dymicka-Piekarska, V.
Cepowicz, D.
Jagodzińska, D.
Lewczuk, Ł.
Lebelt, A.
Ozimkiewicz, M.
Kiszło, P.
Guzińska-Ustymowicz, K.
Powiązania:
https://bibliotekanauki.pl/articles/1917712.pdf
Data publikacji:
2016
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Colorectal cancer
Growth differentiation factor-15
macrophage inhibitory cytokine-1
serum.
Opis:
Purpose: Growth differentiation factor-15 (GDF- 15) protein belongs to a transforming growth factor-β family which determines the growth and differentiation of cells. In cancers, GDF-15 influences on the proliferation, differentiation, viability, migration and invasiveness of cancer cells. The aim of our study was to evaluate the expression of GDF-15 in the tissue and its levels in sera of patients with colorectal cancer. Materials and methods: The level of GDF-15 in the sera of 55 patients diagnosed with colorectal cancer was determined using the ELISA method whereas expression of this protein was performed by immunohistochemical method. Results: The mean value of GDF-15 levels in the sera of patients with colorectal cancer was significantly higher than in healthy control group (p<0.001). The expression of GDF-15 in the tissue was weak, moderate and strong in 23.6%, 15.7% and 60.7% cases, respectively. Statistical analysis showed that the expression of GDF-15 correlated with patients’ age (p<0.005) and non-mucinous type of cancer (p<0.001). The high GDF-15 levels in the serum was associated with tumor size (p<0.01) and distant metastases (p<0.05). Conclusions: According to our results, we postulate that the level of GDF-15 in serum can be use to assess the metastatic behavior of colorectal cancer
Źródło:
Progress in Health Sciences; 2016, 6(1); 40-48
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
A long clinical course with late distant metastases from follicular thyroid carcinoma
Autorzy:
Erok, Berrin
Harmancı, Kemal
Aksaray, Ferdi
Unlu, Nazmi Uğur
Aydın, Seckin
Powiązania:
https://bibliotekanauki.pl/articles/2040497.pdf
Data publikacji:
2021-12-30
Wydawca:
Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:
follicular thyroid carcinoma
brain metastasis
skull metastasis
Opis:
Introduction. Follicular thyroid carcinoma (FTC) accounts for 10-20% of the differentiated thyroid carcinomas (DTCs), and it is the second most common thyroid malignancy after papillary thyroid carcinoma (PTC). FTC is typically more common in women and in older age group than PTC. Unlike PTC, FTC metastases late to the lymph nodes, with only up to 10-20% of the patients having nodal metastases at the time of diagnosis.On the other hand, distant metastasis via hematogenous spread is more likely in patients with FTC due to the invasion of blood vessels. Prognosis depends on the extent of the distant metastasis which drop 10-year survival significantly. Aim. Although DTCs have usually favorable prognosis, metastatic disease in these patients has a long clinical course. Cranial imaging in these patients should be performed during the follow-up after the treatment of FTC with thyroidectomy and RAI. Description of the case. We report a case of late onset but catastrophic hematogenous distant metastases beginning 8 years after the diagnosis & treatment of FTC and becommimg widespread during the following 10 years with a long clinical course in a 60 year old female patient. Conclusion. In the RAI refractory metastatic lesions SRS and surgical resections should be conserned as the first management approach to improve survival.
Źródło:
European Journal of Clinical and Experimental Medicine; 2021, 4; 347-351
2544-2406
2544-1361
Pojawia się w:
European Journal of Clinical and Experimental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-4 z 4

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies